Re-treatment using cetuximab and chemotherapy in patients with metastatic colorectal cancer harboring wild-type RAS gene

Kakil Ibrahim Rasul


Colorectal cancer is a heterogeneous disease. Activating mutations in genes like K-RAS, BRAF, and PI3K contribute towards a poor prognosis of the disease. In this report, we present the case of re-treatment of a 58-year old patient of metastatic colorectal cancer with a combination of anti-EGFR and chemotherapy. The patient who harbored wild-type RAS gene was administered several lines of therapies including anti-EGFR antibodies. In spite of the different regimens involved, a significant progression of disease involving metastasis to the lungs and the brain was observed. On re-treatment with cetuximab and chemotherapy, the quality of life improved and the tumor biomarkers decreased. Re-treatment with anti-EGFR antibodies and chemotherapeutic agents can be an option for patients showing adverse prognosis after several lines of therapies. 


Metastatic colorectal cancer; anti-EGFR antibodies; cetuximab; K-RAS; chemotherapy

Full Text:




  • There are currently no refbacks.

Copyright (c) 2019 Kakil Ibrahim Rasul

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.